全文获取类型
收费全文 | 1469篇 |
免费 | 63篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 55篇 |
妇产科学 | 21篇 |
基础医学 | 116篇 |
口腔科学 | 58篇 |
临床医学 | 191篇 |
内科学 | 293篇 |
皮肤病学 | 38篇 |
神经病学 | 175篇 |
特种医学 | 269篇 |
外科学 | 75篇 |
综合类 | 42篇 |
预防医学 | 74篇 |
眼科学 | 25篇 |
药学 | 66篇 |
中国医学 | 4篇 |
肿瘤学 | 101篇 |
出版年
2021年 | 11篇 |
2020年 | 13篇 |
2019年 | 24篇 |
2018年 | 17篇 |
2017年 | 11篇 |
2016年 | 15篇 |
2015年 | 20篇 |
2014年 | 28篇 |
2013年 | 34篇 |
2012年 | 40篇 |
2011年 | 48篇 |
2010年 | 45篇 |
2009年 | 58篇 |
2008年 | 33篇 |
2007年 | 61篇 |
2006年 | 37篇 |
2005年 | 41篇 |
2004年 | 28篇 |
2003年 | 24篇 |
2002年 | 28篇 |
2001年 | 38篇 |
2000年 | 32篇 |
1999年 | 17篇 |
1998年 | 89篇 |
1997年 | 75篇 |
1996年 | 67篇 |
1995年 | 60篇 |
1994年 | 50篇 |
1993年 | 52篇 |
1992年 | 28篇 |
1991年 | 29篇 |
1990年 | 30篇 |
1989年 | 43篇 |
1988年 | 39篇 |
1987年 | 48篇 |
1986年 | 33篇 |
1985年 | 35篇 |
1984年 | 23篇 |
1983年 | 20篇 |
1982年 | 20篇 |
1981年 | 16篇 |
1980年 | 17篇 |
1979年 | 13篇 |
1978年 | 10篇 |
1977年 | 19篇 |
1976年 | 15篇 |
1975年 | 22篇 |
1974年 | 7篇 |
1973年 | 6篇 |
1967年 | 5篇 |
排序方式: 共有1607条查询结果,搜索用时 15 毫秒
81.
The angiogenic inducer CYR61 is differentially overexpressed in breast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with a metastatic breast cancer phenotype. Here, we examined whether CYR61, independently of HRG, actively regulates breast cancer cell survival and chemosensitivity, and the pathways involved. Forced expression of CYR61 in HRG-negative MCF-7 cells notably upregulated the expression of its own integrin receptor alphavbeta3 (>200 times). Small peptidomimetic alphavbeta3 integrin antagonists dramatically decreased cell viability of CYR61-overexpressing MCF-7 cells, whereas control MCF-7/V remained insensitive. Mechanistically, functional blockade of alphavbeta3 specifically abolished CYR6-induced hyperactivation of ERK1/ERK2 MAPK, whereas the activation status of AKT did not decrease. Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (>10-fold) to Taxol-induced cytotoxicity. Remarkably, alphavbeta3 inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one. Thus, the augmentation of Taxol-induced apoptotic cell death in the presence of alphavbeta3 antagonists demonstrated a strong synergism as verified by the terminal transferase-mediated dUTP nick-end labeling (TUNEL) assay and by flow cytometric analysis for DNA content. Indeed, functional blockade of alphavbeta3, similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G2 phase of the cell cycle and the appearance of sub-G1 hypodiploid (apoptotic) cells caused by Taxol. Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53. Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol. Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a alphavbeta3-activated ERK1/ERK2 MAPK signaling. The identification of a 'CYR61-alphavbeta3 autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting alphavbeta3 may simultaneously prevent breast cancer angiogenesis, growth, and chemoresistance. 相似文献
82.
83.
Nicholas A. E. Russinovich M.D. L. Keith Lloyd W. P. Griggs H. Peter Jander 《Urologic radiology》1981,2(1):33-37
Postinflammatory and posttraumatic urethral strictures present a significant clinical problem. Conventional dilatation techniques are usually associated with recurrence and aggravation of the strictures. This is attributed to the mucosal and periurethral trauma associated with conventional dilatation methods. The initial results in seven patients undergoing balloon dilatation for urethral strictures are presented. The method is relatively atraumatic and painless, and better long-term results are anticipated. 相似文献
84.
Postembolic colonic infarction 总被引:12,自引:0,他引:12
85.
86.
87.
88.
Griggs J Hesketh R Smith GA Brindle KM Metcalfe JC Thomas GA Williams ED 《British journal of cancer》2001,84(6):832-835
Combretastatin-A4 phosphate (cis-CA-4) is a tubulin-binding agent currently undergoing clinical trials as an anti-tumour drug. We have investigated whether CA-4 functions as a tumour-specific anti-vascular agent using the hyperplastic thyroid as a novel in vivo model of neovascularization. CA-4 elicited pathological changes in normal tissue, manifested as the induction of multiple, discrete intravascular thrombi. These vascular-damaging effects indicate that CA-4P does not function as a tumour-specific agent but targets neovasculature irrespective of the primary angiogenic stimulus. 相似文献
89.
Griggs J Brindle KM Metcalfe JC Hill SA Smith GA Beauregard DA Hesketh R 《International journal of oncology》2001,19(4):821-825
The requirement for tumour vascularisation to permit the expansion of solid tumours beyond a threshold size of approximately 1 mm diameter has focussed attention on anti-vascular and anti-angiogenic agents for cancer therapy. Combretastatin-A4 (cis CA-4P) is a tubulin-binding agent that is cytotoxic for proliferating endothelial cells in vitro and causes anti-vascular effects in the established tumour vessels of some primary tumours. Preliminary data from Phase I clinical trials indicate that cis CA-4 may also be effective in targeting the vasculature of human tumours. As metastatic disease is the principal cause of mortality in cancer, we have investigated the effects of cis CA-4 on metastatic development using an in vivo model. We show that bolus or continuous administration of cis CA-4P results in potent inhibition of metastases derived from ectopic primary Lewis lung carcinomas in mice whereas the trans CA-4 isomer is without effect. These data further characterise the activity of CA-4 in vivo and suggest that the drug should be evaluated clinically as an anti-metastatic agent. 相似文献
90.
甲硝唑葡萄糖注射液细菌内毒素检查法的研究 总被引:1,自引:0,他引:1
目的;以细菌内毒素检查法对甲硝唑葡萄糖注射液进行试验研究。方法;采用抑制或增强试验,并将细菌内毒素检查法与家兔法检测结果作对比。结果:该注射液经一定稀释后对测定无干扰。结论:细菌内毒素检查法适用于检测该注射液。 相似文献